Clinical Trial Update: Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial of sunitinib malate in adults with unresectable or metastatic kidney cancer and other advanced solid tumors. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma | Phase 1 | Status: COMPLETED